Kongming Wu

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 41

Top Venues

Journal of hematology & oncology

Experimental hematology & oncology

Molecular cancer

Cancer communications (London, England)

Huazhong University of Science and Technology

Chinese Academy of Medical Sciences and Peking Union Medical College (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Huazhong University of Science and Technology

China

Professor/Principle Investigator :: Oncology

Education History

Chinese Academy of Medical Sciences and Peking Union Medical College

China

PHD :: Oncology

Zhengzhou University Medical College

China

MSC :: Pharmacology

Publications

Yuze Wu, Ming Yi, Mengke Niu, Binghan Zhou, Qi Mei, Kongming Wu
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors. Cancer communications (London, England) 44 (7) (2024)
Ming Yi, Tianye Li, Mengke Niu, Yuze Wu, Bin Zhao, Zhuoyang Shen, Shengtao Hu, Chaomei Zhang, Xiaojun Zhang, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Qian Chu, Zhijun Dai, Kongming Wu
Blockade of CCR5 + T Cell Accumulation in the Tumor Microenvironment Optimizes Anti-TGF-β/PD-L1 Bispecific Antibody. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024)
Yuze Wu, Ming Yi, Mengke Niu, Binghan Zhou, Qi Mei, Kongming Wu
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors. Cancer communications (London, England) 44 (7) (2024)
Yuze Wu, Ming Yi, Mengke Niu, Binghan Zhou, Qi Mei, Kongming Wu
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors. Cancer communications (London, England) 44 (7) (2024)
Yuze Wu, Ming Yi, Mengke Niu, Binghan Zhou, Qi Mei, Kongming Wu
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors. Cancer communications (London, England) (2024)
Ming Yi, Yuze Wu, Mengke Niu, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Zhijun Dai, Kongming Wu
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. Journal for immunotherapy of cancer 10 (12) (2022)
Hanxiao Xu, Dechao Jiao, Aiguo Liu, Kongming Wu
Tumor organoids: applications in cancer modeling and potentials in precision medicine. Journal of hematology & oncology 15 (1) (2022)
Dewei Jiang, Ting Qiu, Junjiang Peng, Siyuan Li, null Tala, Wenlong Ren, Chuanyu Yang, Yi Wen, Chuan-Huizi Chen, Jian Sun, Yingying Wu, Rong Liu, Jun Zhou, Kongming Wu, Wen Liu, Xiaoyun Mao, Zhongmei Zhou, Ceshi Chen
YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer. Cell death and differentiation 29 (6) (2022)
Shuangli Zhu, Ming Yi, Yuze Wu, Bing Dong, Kongming Wu
Correction to: Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Experimental hematology & oncology 11 (1) (2022)
Ming Yi, Xiaoli Zheng, Mengke Niu, Shuangli Zhu, Hong Ge, Kongming Wu
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Molecular cancer 21 (1) (2022)
Shuangli Zhu, Ming Yi, Yuze Wu, Bing Dong, Kongming Wu
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Experimental hematology & oncology 10 (1) (2021)
Ming Yi, Mengke Niu, Linping Xu, Suxia Luo, Kongming Wu
Regulation of PD-L1 expression in the tumor microenvironment. Journal of hematology & oncology 14 (1) (2021)
Bing Dong, Shiyu Li, Shuangli Zhu, Ming Yi, Suxia Luo, Kongming Wu
MiRNA-mediated EMT and CSCs in cancer chemoresistance. Experimental hematology & oncology 10 (1) (2021)
Yuze Wu, Ming Yi, Shuangli Zhu, Haiyong Wang, Kongming Wu
Recent advances and challenges of bispecific antibodies in solid tumors. Experimental hematology & oncology 10 (1) (2021)
Ming Yi, Mengke Niu, Jing Zhang, Shiyu Li, Shuangli Zhu, Yongxiang Yan, Ning Li, Pengfei Zhou, Qian Chu, Kongming Wu
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. Journal of hematology & oncology 14 (1) (2021)
Ming Yi, Anping Li, Linghui Zhou, Qian Chu, Suxia Luo, Kongming Wu
Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma. Cancer immunology, immunotherapy : CII 70 (6) (2021)
Ming Yi, Jing Zhang, Anping Li, Mengke Niu, Yongxiang Yan, Ying Jiao, Suxia Luo, Pengfei Zhou, Kongming Wu
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1. Journal of hematology & oncology 14 (1) (2021)
Ming Yi, Anping Li, Linghui Zhou, Qian Chu, Yongping Song, Kongming Wu
The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. Journal of hematology & oncology 13 (1) (2020)
Ming Yi, Tianye Li, Shuang Qin, Shengnan Yu, Qian Chu, Anping Li, Kongming Wu
Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis. BioMed research international 2020 (2020)
Ming Yi, Linping Xu, Ying Jiao, Suxia Luo, Anping Li, Kongming Wu
The role of cancer-derived microRNAs in cancer immune escape. Journal of hematology & oncology 13 (1) (2020)
Shiyu Li, Ming Yi, Bing Dong, Ximin Tan, Suxia Luo, Kongming Wu
The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. International journal of cancer 148 (11) (2020)
Ming Yi, Dechao Jiao, Shuang Qin, Qian Chu, Anping Li, Kongming Wu
Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. Integrative cancer therapies 18 (2020)
Xianguang Bai, Ming Yi, Bing Dong, Xinhua Zheng, Kongming Wu
The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017. Experimental hematology & oncology 9 (2020)
Bing Dong, Ming Yi, Suxia Luo, Anping Li, Kongming Wu
RDGN-based predictive model for the prognosis of breast cancer. Experimental hematology & oncology 9 (2020)
Ming Yi, Dechao Jiao, Shuang Qin, Qian Chu, Kongming Wu, Anping Li
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Molecular cancer 18 (1) (2019)
Ming Yi, Bing Dong, Shuang Qin, Qian Chu, Kongming Wu, Suxia Luo
Advances and perspectives of PARP inhibitors. Experimental hematology & oncology 8 (2019)
Xianguang Bai, Ming Yi, Ying Jiao, Qian Chu, Kongming Wu
Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor. OncoTargets and therapy 12 (2019)
Shuang Qin, Linping Xu, Ming Yi, Shengnan Yu, Kongming Wu, Suxia Luo
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Molecular cancer 18 (1) (2019)
Ming Yi, Bing Dong, Qian Chu, Kongming Wu
Immune pressures drive the promoter hypermethylation of neoantigen genes. Experimental hematology & oncology 8 (2019)
Shengnan Yu, Ming Yi, Shuang Qin, Kongming Wu
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Molecular cancer 18 (1) (2019)
Kongju Wu, Ming Yi, Shuang Qin, Qian Chu, Xinhua Zheng, Kongming Wu
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. Experimental hematology & oncology 8 (2019)
Anping Li, Ming Yi, Shuang Qin, Yongping Song, Qian Chu, Kongming Wu
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. Journal of hematology & oncology 12 (1) (2019)
Shuang Qin, Anping Li, Ming Yi, Shengnan Yu, Mingsheng Zhang, Kongming Wu
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. Journal of hematology & oncology 12 (1) (2019)
Anping Li, Ming Yi, Shuang Qin, Qian Chu, Suxia Luo, Kongming Wu
Prospects for combining immune checkpoint blockade with PARP inhibition. Journal of hematology & oncology 12 (1) (2019)
Qian Liu, Shengnan Yu, Weiheng Zhao, Shuang Qin, Qian Chu, Kongming Wu
EGFR-TKIs resistance via EGFR-independent signaling pathways. Molecular cancer 17 (1) (2018)
Ming Yi, Dechao Jiao, Hanxiao Xu, Qian Liu, Weiheng Zhao, Xinwei Han, Kongming Wu
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Molecular cancer 17 (1) (2018)
Ming Yi, Shengnan Yu, Shuang Qin, Qian Liu, Hanxiao Xu, Weiheng Zhao, Qian Chu, Kongming Wu
Gut microbiome modulates efficacy of immune checkpoint inhibitors. Journal of hematology & oncology 11 (1) (2018)
Hanxiao Xu, Xiaodong Lyu, Ming Yi, Weiheng Zhao, Yongping Song, Kongming Wu
Organoid technology and applications in cancer research. Journal of hematology & oncology 11 (1) (2018)
Qian Liu, Anping Li, Shengnan Yu, Shuang Qin, Na Han, Richard G Pestell, Xinwei Han, Kongming Wu
DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis. Journal of hematology & oncology 11 (1) (2018)
Yutao Xiao, Qing Dai, Ruqin Hu, Sabino Pacheco, Yongbo Yang, Gemei Liang, Mario Soberón, Alejandra Bravo, Kaiyu Liu, Kongming Wu
A Single Point Mutation Resulting in Cadherin Mislocalization Underpins Resistance against Bacillus thuringiensis Toxin in Cotton Bollworm. The Journal of biological chemistry 292 (7) (2017)
Hanxiao Xu, Shengnan Yu, Xun Yuan, Jing Xiong, Dong Kuang, Richard G Pestell, Kongming Wu
DACH1 suppresses breast cancer as a negative regulator of CD44. Scientific reports 7 (1) (2017)

Kongming Wu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Kongming Wu